Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial
…, C Kase, M Pessin, A Ahuja, F Callahan, WM Clark… - Jama, 1999 - jamanetwork.com
ContextIntravenous tissue-type plasminogen activator can be beneficial to some patients
when given within 3 hours of stroke onset, but many patients present later after stroke onset …
when given within 3 hours of stroke onset, but many patients present later after stroke onset …
[HTML][HTML] Stenting versus endarterectomy for treatment of carotid-artery stenosis
…, G Howard, GS Roubin, WM Clark… - … England Journal of …, 2010 - Mass Medical Soc
Background Carotid-artery stenting and carotid endarterectomy are both options for treating
carotid-artery stenosis, an important cause of stroke. Methods We randomly assigned …
carotid-artery stenosis, an important cause of stroke. Methods We randomly assigned …
[HTML][HTML] Endovascular therapy after intravenous t-PA versus t-PA alone for stroke
…, BM Demaerschalk, R Budzik, WM Clark… - … England Journal of …, 2013 - Mass Medical Soc
Background Endovascular therapy is increasingly used after the administration of intravenous
tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic …
tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic …
Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial
WM Clark, S Wissman, GW Albers, JH Jhamandas… - Jama, 1999 - jamanetwork.com
ContextRecombinant tissue-type plasminogen activator (rt-PA) improves outcomes for
patients with acute ischemic stroke, but current approved use is limited to within 3 hours of …
patients with acute ischemic stroke, but current approved use is limited to within 3 hours of …
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study
GW Albers, VE Bates, WM Clark, R Bell, P Verro… - Jama, 2000 - jamanetwork.com
ContextTissue-type plasminogen activator (tPA) is the only therapy for acute ischemic stroke
approved by the Food and Drug Administration.ObjectiveTo assess the safety profile and to …
approved by the Food and Drug Administration.ObjectiveTo assess the safety profile and to …
[HTML][HTML] Long-term results of stenting versus endarterectomy for carotid-artery stenosis
…, MD Hill, VA Mantese, WM Clark… - … England Journal of …, 2016 - Mass Medical Soc
Background In the Carotid Revascularization Endarterectomy versus Stenting Trial, we found
no significant difference between the stenting group and the endarterectomy group with …
no significant difference between the stenting group and the endarterectomy group with …
The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) Results of a double-blind, placebo-controlled, multicenter study
WM Clark, GW Albers, KP Madden, S Hamilton - Stroke, 2000 - Am Heart Assoc
Background and Purpose—The Thrombolytic Therapy in Acute Ischemic Stroke Study, which
started in August of 1991, was designed to assess the efficacy and safety of intravenous …
started in August of 1991, was designed to assess the efficacy and safety of intravenous …
Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials
Background and Purpose— No single neuroprotective agent has been shown to influence
outcome after acute stroke. Citicoline has been studied worldwide in many clinical trials with …
outcome after acute stroke. Citicoline has been studied worldwide in many clinical trials with …
Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled …
…, JH Wong, FL Silver, G Milot, WM Clark… - The Lancet …, 2012 - thelancet.com
Background Neuroprotection with NA-1 (Tat-NR2B9c), an inhibitor of postsynaptic density-95
protein, has been shown in a primate model of stroke. We assessed whether NA-1 could …
protein, has been shown in a primate model of stroke. We assessed whether NA-1 could …
A randomized dose-response trial of citicoline in acute ischemic stroke patients
WM Clark, SJ Warach, LC Pettigrew, RE Gammans… - Neurology, 1997 - AAN Enterprises
Citicoline (CDP-choline) is a key intermediary in the biosynthesis of phosphatidylcholine, an
important component of the neural cell membrane. It has been shown to produce beneficial …
important component of the neural cell membrane. It has been shown to produce beneficial …